Boston-area teaching hospitals and universities are bracing for deep cuts in the federal funding that has fueled biomedical research for decades, raising fears that breakthrough work on cancer cures, stem cells, gene therapy, and other research will suffer setbacks. Bill Chin, executive dean for research; Lee Nadler, dean for clinical and translational research; Peter L. Slavin, president of Massachusetts General Hospital; Stirling Churchman, HMS assistant professor of genetics; and David Scadden, professor of stem cell and regenerative biology, are quoted.
